<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04858594</url>
  </required_header>
  <id_info>
    <org_study_id>2020LS191</org_study_id>
    <secondary_id>HM2020-37</secondary_id>
    <nct_id>NCT04858594</nct_id>
  </id_info>
  <brief_title>Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy</brief_title>
  <official_title>Effect of Periodontitis on the Risk of Bloodstream Infection During Intensive Chemotherapy in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational study to establish the connection between periodontitis&#xD;
      and BSI in AML patients planning to receive intensive chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Once eligibility is confirmed, participants will undergo a specialized baseline periodontal&#xD;
      examination, gingival sulcus microbiota sampling and saliva sample at baseline before&#xD;
      starting chemotherapy.&#xD;
&#xD;
      Patients will be separated into 2 cohorts, with periodontitis (Arm A) and without&#xD;
      periodontitis (Arm B). All patients will receive standard oncologic supportive care including&#xD;
      antibiotic prophylaxis. Serum samples will be obtained at baseline, at the onset of&#xD;
      neutropenic fever, and weekly until day 28 or discharge (whichever sooner).&#xD;
&#xD;
      Study participation will continue during the duration of standard of care chemotherapy for 28&#xD;
      days or until discharge from hospital, whichever later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Blood stream infections</measure>
    <time_frame>Day 28 of chemotherapy</time_frame>
    <description>Number of participants experiencing Blood stream infections (BSI) by day 28 of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Neutropenic fever</measure>
    <time_frame>Day 28 of chemotherapy</time_frame>
    <description>Number of participants experiencing Neutropenic fever (NF) by day 28 of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants exposed to different antibiotics</measure>
    <time_frame>Day 28 of chemotherapy</time_frame>
    <description>Number of participants with antibiotic exposure by day 28 of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Day 28 of chemotherapy</time_frame>
    <description>Number of days the patients were hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who died</measure>
    <time_frame>Day 28 of chemotherapy</time_frame>
    <description>Number of participants who died by day 28 of chemotherapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A: with Periodontitis</arm_group_label>
    <description>Patients with periodontitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: without Periodontitis</arm_group_label>
    <description>Patients without periodontitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Planned Chemotherapy</intervention_name>
    <description>standard oncologic supportive care including antibiotic prophylaxis</description>
    <arm_group_label>Arm A: with Periodontitis</arm_group_label>
    <arm_group_label>Arm B: without Periodontitis</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Research samples of gingival sulcus fluid, saliva and serum will be collected at baseline.&#xD;
      Additionally the blood will be collected weekly through day 28 (or discharge if sooner), and&#xD;
      if the patient develops neutropenic fever NF. NF is defined as an oral temperature of&#xD;
      ≥100.4°F combined with an absolute neutrophil count (ANC) of ≤0.5x10^9/L^10&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study entry is open to adult patients regardless of gender, race or ethnic background.&#xD;
        While there will be every effort to seek out and include women and minority patients, the&#xD;
        patient population is expected to be similar to that of other relapsed AML studies at the&#xD;
        University Of Minnesota&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Diagnosis of AML, new diagnosis or relapsed/refractory disease&#xD;
&#xD;
          -  Planned intensive inpatient chemotherapy, defined as expected hospitalization for 4&#xD;
             weeks or longer&#xD;
&#xD;
          -  Sufficient time to perform periodontal examination and treatment by the end of day 1&#xD;
             of chemotherapy without delaying chemotherapy&#xD;
&#xD;
          -  Written informed consent prior to performance of any research related activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable for transfer to the School of Dentistry&#xD;
&#xD;
          -  Fever at the time of enrollment&#xD;
&#xD;
          -  Documented blood stream infection at the time of enrollment&#xD;
&#xD;
          -  Inherited bleeding diathesis&#xD;
&#xD;
          -  Periodontitis requiring treatment before starting chemotherapy&#xD;
&#xD;
          -  ANC &lt;0.5 x 10^9/L at the time of enrollment&#xD;
&#xD;
          -  Unstable for transfer to the School of Dentistry&#xD;
&#xD;
          -  Fever at the time of enrollment&#xD;
&#xD;
          -  Documented blood stream infection at the time of enrollment&#xD;
&#xD;
          -  Inherited bleeding diathesis&#xD;
&#xD;
          -  Periodontitis requiring treatment before starting chemotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armin Rashidi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armin Rashidi, MD, PhD</last_name>
    <phone>612-625-1110</phone>
    <email>arashidi@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>April 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BSI</keyword>
  <keyword>Periodontitis</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

